Funds totaling £5.5 million have been secured by a health technology startup for the development of a device that monitors hormone levels.

In an exciting development for the healthcare industry, healthtech startup Level Zero Health has secured a £5.5 million pre-seed funding round. This funding will propel the company towards bringing its revolutionary hormone monitoring solution to market.

Founded by Ula Rustamova, ex-Palantir Enterprise Tech Lead, and Irene Jia, who developed medical devices at Philips, Level Zero Health is developing a breakthrough technology for remote and continuous hormone monitoring using DNA-based sensors.

The technology could transform multiple areas of healthcare, including In Vitro Fertilisation (IVF), menopause, and testosterone replacement therapy (TRT). According to Aaron Styer, medical director at CCRM Fertility and an associate professor at Harvard Medical School, who serves as an advisor to Level Zero Health, the technology will significantly enhance the clinician's ability to manage and monitor hormonal-based diseases and treatments.

Level Zero Health's sensors detect hormone levels in interstitial fluid, eliminating the need for blood draws. This minimally invasive approach could expand patient access to care, reduce healthcare costs, and enable clinicians to change the paradigm of medical practice.

The funding round was spearheaded by European VC redalpine, with contributions from HAX (SOSV), Entrepreneur First, and industry experts. Philip Kneis, an investor at redalpine and board member of Level Zero Health, expressed his excitement about the company's mission to transform hormone tracking with its novel biosensor.

Initially, Level Zero Health is targeting B2B clinical applications, but has positioned itself for potential B2C and pharma expansion. Ula Rustamova, CEO of Level Zero Health, commented that the funding will enable them to bring this revolutionary hormone monitoring solution to market.

The device, a sleek wearable patch, attaches to the user's arm and delivers real-time measurements of stress and reproductive hormones. This technology has a myriad of applications across remote hormonal monitoring for fertility treatments and endocrine disorders.

Femtech innovation in menopause is the next big thing in the femtech industry. The approval of Inne's saliva test marks a new era for contraception. Level Zero Health's innovation in this field could revolutionise the way we approach and manage hormonal conditions, particularly in the context of menopause and testosterone replacement therapy.

With an impressive pipeline of customers already established, Level Zero Health is poised to make a significant impact in the healthcare industry. The funding will be used for research and development, bringing the product to market, and expanding the team.

This funding round is a testament to the potential of Level Zero Health's technology and the team's dedication to transforming hormone tracking. As the company continues to grow and develop, we can look forward to a future where hormonal health management is more accessible, efficient, and precise.